{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:23:08Z","timestamp":1792113788100,"version":"4.4.0"},"reference-count":147,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52173150"],"award-info":[{"award-number":["52173150"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20315"],"award-info":[{"award-number":["U22A20315"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515111126"],"award-info":[{"award-number":["2023A1515111126"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2024A03J0604"],"award-info":[{"award-number":["2024A03J0604"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2024A03J0431"],"award-info":[{"award-number":["2024A03J0431"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.actbio.2026.01.043","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T07:49:32Z","timestamp":1769240972000},"page":"103-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Nanotechnology-driven biomaterials for chronic liver diseases: Stage-specific strategies for advanced theranostics"],"prefix":"10.1016","volume":"212","author":[{"given":"Yishui","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2026.01.043_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661182","article-title":"Macrophages in chronic liver failure: diversity, plasticity and therapeutic targeting","volume":"12","author":"Singanayagam","year":"2021","journal-title":"Front. Immunol"},{"key":"10.1016\/j.actbio.2026.01.043_bib0002","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41392-024-02072-z","article-title":"Liver diseases: epidemiology, causes, trends and predictions","volume":"10","author":"Gan","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.actbio.2026.01.043_bib0003","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0004","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.actbio.2026.01.043_bib0006","article-title":"Ethnic differences in metabolic and histologic features among white, hispanic, black and asian patients with metabolic-associated steatotic liver disease: a network meta-analysis","volume":"30","author":"L","year":"2025","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0007","doi-asserted-by":"crossref","first-page":"goae069","DOI":"10.1093\/gastro\/goae069","article-title":"Current epidemiology of chronic liver disease","volume":"12","author":"Manikat","year":"2023","journal-title":"Gastroenterol. Rep."},{"key":"10.1016\/j.actbio.2026.01.043_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156004","article-title":"Metabolic dysfunction-associated steatotic liver disease and its link to cancer","volume":"160","author":"Kalligeros","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.actbio.2026.01.043_bib0009","article-title":"Diagnosis and treatment of liver disease: current trends and future directions","volume":"15","author":"Wazir","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.actbio.2026.01.043_bib0010","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis","volume":"398","author":"Gin\u00e8s","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.actbio.2026.01.043_bib0011","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/livers4030031","article-title":"Transplant immunology in liver Transplant, rejection, and tolerance","volume":"4","author":"Yokoyama","year":"2024","journal-title":"Livers"},{"key":"10.1016\/j.actbio.2026.01.043_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122318","article-title":"Exploring the impact of severity in hepatic fibrosis disease on the intrahepatic distribution of novel biodegradable nanoparticles targeted towards different disease biomarkers","volume":"302","author":"Balaji","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2026.01.043_bib0013","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40820-020-00550-x","article-title":"Applications of nanobiomaterials in the therapy and imaging of acute liver failure","volume":"13","author":"Jin","year":"2021","journal-title":"Nano-Micro Lett"},{"key":"10.1016\/j.actbio.2026.01.043_bib0014","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s42765-024-00395-8","article-title":"Nanofiber scaffold-based tissue engineering for the treatment of acute liver failure","volume":"6","author":"Liu","year":"2024","journal-title":"Adv. Fiber Mater."},{"key":"10.1016\/j.actbio.2026.01.043_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2025.1661872","article-title":"Nanoparticle technologies for liver targeting and their applications in liver diseases","volume":"13","author":"Peng","year":"2025","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0016","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1186\/s12951-024-02892-9","article-title":"Nanocarriers for targeted drug delivery in the vascular system: focus on endothelium","volume":"22","author":"Cong","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0017","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.addr.2006.09.009","article-title":"Multifunctional nanocarriers","volume":"58","author":"Torchilin","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2026.01.043_bib0018","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","article-title":"Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs","volume":"8","author":"Dilliard","year":"2023","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.actbio.2026.01.043_bib0019","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.bios.2005.10.027","article-title":"Electrochemical biosensors: towards point-of-care cancer diagnostics","volume":"21","author":"Wang","year":"2006","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.actbio.2026.01.043_bib0020","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.actbio.2026.01.043_bib0021","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.3748\/wjg.v24.i27.2974","article-title":"Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from \u201ctwo hit theory\u201d to \u201cmultiple hit model","volume":"24","author":"Fang","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0022","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1172\/JCI24930","article-title":"Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease","volume":"115","author":"Tamura","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.actbio.2026.01.043_bib0023","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.actbio.2026.01.043_bib0024","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2337\/dc20-1644","article-title":"Hepatic insulin resistance is not pathway selective in humans with nonalcoholic fatty liver disease","volume":"44","author":"ter Horst","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.actbio.2026.01.043_bib0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2174\/157339910793360879","article-title":"Interrelationships between hepatic fat and insulin resistance in non- alcoholic fatty liver disease","volume":"6","author":"Lockman","year":"2010","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.actbio.2026.01.043_bib0026","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.actbio.2026.01.043_bib0027","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.plipres.2012.10.004","article-title":"Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease","volume":"52","year":"2013","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.actbio.2026.01.043_bib0028","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease","volume":"48","author":"Kawano","year":"2013","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0029","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.actbio.2026.01.043_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2023.1110536","article-title":"Gut microbiota modulation in patients with non-alcoholic fatty liver disease: effects of current treatments and future strategies","volume":"10","author":"Maestri","year":"2023","journal-title":"Front. Nutr."},{"key":"10.1016\/j.actbio.2026.01.043_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120576","article-title":"Inositol hexanicotinate self-micelle solid dispersion is an efficient drug delivery system in the mouse model of non-alcoholic fatty liver disease","volume":"602","author":"Zheng","year":"2021","journal-title":"Int J. Pharm."},{"key":"10.1016\/j.actbio.2026.01.043_bib0032","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1021\/acs.molpharmaceut.8b00548","article-title":"Polyurethane nanoparticle-loaded fenofibrate exerts inhibitory effects on nonalcoholic fatty liver disease in mice","volume":"15","author":"Cao","year":"2018","journal-title":"Mol. Pharm"},{"key":"10.1016\/j.actbio.2026.01.043_bib0033","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3390\/pharmaceutics17040480","article-title":"Preparation and therapeutic evaluation of engineered semaglutide and statin\u2013Lipid conjugate-based nanoparticle","volume":"17","author":"Lee","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.actbio.2026.01.043_bib0034","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2022.04.034","article-title":"Celastrol-loaded lactosylated albumin nanoparticles attenuate hepatic steatosis in non-alcoholic fatty liver disease","volume":"347","author":"Fan","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2026.01.043_bib0035","article-title":"Construction of glycogen-based nanoparticles loaded with resveratrol for the alleviation of high-fat diet-induced nonalcoholic fatty liver disease","author":"Li","year":"2021","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.actbio.2026.01.043_bib0036","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1039\/D2FO04036K","article-title":"Hepatic parenchymal cell and mitochondrial-targeted astaxanthin nanocarriers for relief of high fat diet-induced nonalcoholic fatty liver disease","volume":"14","author":"Che","year":"2023","journal-title":"Food Funct."},{"key":"10.1016\/j.actbio.2026.01.043_bib0037","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jconrel.2020.09.008","article-title":"Bioresponsive drug delivery systems for the treatment of inflammatory diseases","volume":"327","author":"Dou","year":"2020","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.actbio.2026.01.043_bib0038","doi-asserted-by":"crossref","first-page":"13249","DOI":"10.1039\/D2NJ01518H","article-title":"H2O2-responsive lovastatin nanohybrids based on auto-fluorescent perylene diimide reverse nonalcoholic fatty liver disease","volume":"46","author":"Xue","year":"2022","journal-title":"New J. Chem."},{"key":"10.1016\/j.actbio.2026.01.043_bib0039","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1021\/acs.molpharmaceut.2c00549","article-title":"Engineered fenofibrate as oxidation-sensitive nanoparticles with ROS scavenging and PPAR\u03b1-activating bioactivity to ameliorate nonalcoholic fatty liver disease","volume":"20","author":"Du","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.actbio.2026.01.043_bib0040","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41575-019-0134-x","article-title":"Spatial heterogeneity in the mammalian liver","volume":"16","author":"Ben-Moshe","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0041","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.redox.2017.01.012","article-title":"Metabolic zonation of the liver: the oxygen gradient revisited","volume":"11","author":"Kietzmann","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0042","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3390\/jfb15080236","article-title":"Chitosan-stabilized selenium nanoparticles alleviate high-fat diet-induced non-alcoholic fatty liver disease (NAFLD) by modulating the gut barrier function and microbiota","volume":"15","author":"Luo","year":"2024","journal-title":"J. Func. Biomater."},{"key":"10.1016\/j.actbio.2026.01.043_bib0043","doi-asserted-by":"crossref","DOI":"10.1002\/sstr.202200312","article-title":"Prebiotic-Based nanoamorphous atorvastatin attenuates nonalcoholic fatty liver disease by retrieving gut and liver health","volume":"4","author":"Cui","year":"2023","journal-title":"Small Struct."},{"key":"10.1016\/j.actbio.2026.01.043_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2023.105734","article-title":"Pomegranate-derived exosome-like nanovesicles ameliorate high-fat diet-induced nonalcoholic fatty liver disease via alleviating mitochondrial dysfunction","volume":"108","author":"Hou","year":"2023","journal-title":"J. Funct. Food"},{"key":"10.1016\/j.actbio.2026.01.043_bib0045","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41401-021-00681-w","article-title":"Blueberry-derived exosomes-like nanoparticles ameliorate nonalcoholic fatty liver disease by attenuating mitochondrial oxidative stress","volume":"43","author":"Zhao","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.actbio.2026.01.043_bib0046","doi-asserted-by":"crossref","first-page":"11319","DOI":"10.1039\/D4FO04321A","article-title":"Advances in plant-derived extracellular vesicles: isolation, composition, and biological functions","volume":"15","author":"Zeng","year":"2024","journal-title":"Food Funct"},{"key":"10.1016\/j.actbio.2026.01.043_bib0047","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.7150\/thno.97096","article-title":"Exosome-like nanoparticles derived from fruits, vegetables, and herbs: innovative strategies of therapeutic and drug delivery","volume":"14","author":"Zhao","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.actbio.2026.01.043_bib0048","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12951-022-01755-5","article-title":"Tea leaf-derived exosome-like nanotherapeutics retard breast tumor growth by pro-apoptosis and microbiota modulation","volume":"21","author":"Chen","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0049","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.apsb.2021.08.016","article-title":"Natural exosome-like nanovesicles from edible tea flowers suppress metastatic breast cancer via ROS generation and microbiota modulation","volume":"12","author":"Chen","year":"2022","journal-title":"Acta Pharm. Sin., B."},{"key":"10.1016\/j.actbio.2026.01.043_bib0050","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3390\/membranes11060411","article-title":"Plant-derived extracellular vesicles: current findings, challenges, and future applications","volume":"11","author":"Kameli","year":"2021","journal-title":"Membranes"},{"key":"10.1016\/j.actbio.2026.01.043_bib0051","first-page":"53","article-title":"Plant-derived exosome-like nanoparticles and their therapeutic activities","volume":"17","author":"Kim","year":"2022","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.actbio.2026.01.043_bib0052","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discovery."},{"key":"10.1016\/j.actbio.2026.01.043_bib0053","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/polym12020298","article-title":"The importance of poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation","volume":"12","author":"Hoang Thi","year":"2020","journal-title":"Polymers"},{"key":"10.1016\/j.actbio.2026.01.043_bib0054","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.actbio.2026.01.043_bib0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-60845-6","article-title":"Assessing the combined impact of fatty liver-induced TGF-\u03b21 and LPS-activated macrophages in fibrosis through a novel 3D serial section methodology","volume":"14","author":"Ishiyama","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.actbio.2026.01.043_bib0056","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3390\/cells10082034","article-title":"NAFLD-related Hepatocarcinoma: the malignant side of metabolic syndrome","volume":"10","author":"Michelotti","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.actbio.2026.01.043_bib0057","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11901-018-0425-7","article-title":"Pathogenesis of NASH: the impact of multiple pathways","volume":"17","author":"Noureddin","year":"2018","journal-title":"Curr. Hepatol. Rep."},{"key":"10.1016\/j.actbio.2026.01.043_bib0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-023-05853-6","article-title":"Butyrate limits inflammatory macrophage niche in NASH","volume":"14","author":"Sarkar","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.actbio.2026.01.043_bib0059","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jpp\/rgad031","article-title":"Chrysin and its nanoliposome ameliorated non-alcoholic steatohepatitis via inhibiting TLR4 signalling pathway","volume":"75","author":"Liu","year":"2023","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0060","doi-asserted-by":"crossref","first-page":"G428","DOI":"10.1152\/ajpgi.00217.2019","article-title":"Nanoformulated SOD1 ameliorates the combined NASH and alcohol-associated liver disease partly via regulating CYP2E1 expression in adipose tissue and liver","volume":"318","author":"Gopal","year":"2020","journal-title":"Am. J. Physiol.-Gastroint. Liver Physiol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0061","article-title":"Lipid peroxide-regulated nanoparticles prevent the progression of nonalcoholic steatohepatitis by reducing lipid deposition and eliminating oxidative-stress","volume":"98","author":"Zhang","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0062","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200468","article-title":"Hepatic-targeted nano-enzyme with resveratrol loading for precise relief of nonalcoholic steatohepatitis","volume":"18","author":"Tong","year":"2023","journal-title":"ChemMedChem"},{"key":"10.1016\/j.actbio.2026.01.043_bib0063","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1021\/acs.molpharmaceut.4c00070","article-title":"Reactive oxygen species-responsive delivery of a notch inhibitor to alleviate nonalcoholic steatohepatitis by inhibiting hepatic de novo lipogenesis and inflammation","volume":"21","author":"Chen","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.actbio.2026.01.043_bib0064","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3390\/biomedicines9081014","article-title":"Extra- and intra-cellular mechanisms of hepatic stellate cell activation","volume":"9","author":"Yan","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.actbio.2026.01.043_bib0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910803","article-title":"The complex interplay of TGF-\u03b2 and notch signaling in the pathogenesis of fibrosis","volume":"25","author":"Bakalenko","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.actbio.2026.01.043_bib0066","doi-asserted-by":"crossref","DOI":"10.1038\/srep18272","article-title":"The interplay of the notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis","volume":"5","author":"Bansal","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.actbio.2026.01.043_bib0067","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jconrel.2024.04.050","article-title":"Metabolic dysfunction-associated steatohepatitis treated by poly(ethylene glycol)-block-poly(cysteine) block copolymer-based self-assembling antioxidant nanoparticles","volume":"370","author":"Koda","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2026.01.043_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2022.102538","article-title":"Platelet-neutrophil hybrid membrane-coated gelatin nanoparticles for enhanced targeting ability and intelligent release in the treatment of non-alcoholic steatohepatitis","volume":"42","author":"Xie","year":"2022","journal-title":"Nanomed.-Nanotechnol. Biol. Med."},{"key":"10.1016\/j.actbio.2026.01.043_bib0069","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41419-020-2571-4","article-title":"Lipid-encapsulated siRNA for hepatocyte-directed treatment of advanced liver disease","volume":"11","author":"Woitok","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.actbio.2026.01.043_bib0070","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2022.01.038","article-title":"Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis","volume":"343","author":"Zhou","year":"2022","journal-title":"J. Control. Release."},{"key":"10.1016\/j.actbio.2026.01.043_bib0071","doi-asserted-by":"crossref","first-page":"14852","DOI":"10.1021\/acsnano.3c03217","article-title":"Nanoparticle-mediated RNA therapy attenuates nonalcoholic steatohepatitis and related fibrosis by targeting activated hepatic stellate cells","volume":"17","author":"Zhang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2026.01.043_bib0072","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1271835","article-title":"Nanoparticles alleviate non-alcoholic steatohepatitis via ER stress sensor-mediated intestinal barrier damage and gut dysbiosis","volume":"14","author":"Zhu","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0073","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1080\/10408398.2023.2297811","article-title":"The health benefits of dietary short-chain fatty acids in metabolic diseases","volume":"65","author":"Tao","year":"2025","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.actbio.2026.01.043_bib0074","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1341938","article-title":"Regulating bile acids signaling for NAFLD: molecular insights and novel therapeutic interventions","volume":"15","author":"Wei","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0075","doi-asserted-by":"crossref","DOI":"10.1002\/asia.202200573","article-title":"Silica-based nanoparticles for enzyme immobilization and delivery","volume":"17","author":"Zhao","year":"2022","journal-title":"Chem.-Asian J."},{"key":"10.1016\/j.actbio.2026.01.043_bib0076","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3390\/v14020434","article-title":"Current trend in antiviral therapy for chronic hepatitis B","volume":"14","author":"Chien","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.actbio.2026.01.043_bib0077","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1080\/14760584.2021.1984890","article-title":"Nanovaccine: an emerging strategy","volume":"20","author":"Das","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.actbio.2026.01.043_bib0078","doi-asserted-by":"crossref","first-page":"12530","DOI":"10.1002\/jcp.28120","article-title":"Nanovaccine: A novel approach in immunization","volume":"234","author":"Gheibi Hayat","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0079","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/cei.13614","article-title":"Therapeutic vaccination for treatment of chronic hepatitis B","volume":"205","author":"Cargill","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0080","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1039\/D2BM00407K","article-title":"A carrier-free metal\u2013organic hybrid nanoassembly with combination anti-viral and hepato-protective activity for hepatitis B treatment","volume":"10","author":"Dong","year":"2022","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.actbio.2026.01.043_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105483","article-title":"Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virus","volume":"209","author":"Lamrayah","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.actbio.2026.01.043_bib0082","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11095-022-03307-w","article-title":"Optimized cationic lipid-assisted nanoparticle for delivering CpG oligodeoxynucleotides to treat hepatitis B virus infection","volume":"40","author":"Chen","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.actbio.2026.01.043_bib0083","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120674","article-title":"Engineered therapeutic nanovaccine against chronic hepatitis B virus infection","volume":"269","author":"Qiao","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2026.01.043_bib0084","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00018-024-05404-y","article-title":"Lymph node-targeted STING agonist nanovaccine against chronic HBV infection","volume":"81","author":"Hu","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.actbio.2026.01.043_bib0085","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.2147\/IJN.S317113","article-title":"Chitosan nanovaccines as efficient carrier adjuvant system for IL-12 with enhanced protection against HBV","volume":"16","author":"Zhao","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.actbio.2026.01.043_bib0086","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.3390\/ijms25147873","article-title":"Liver fibrosis: from basic science towards clinical progress, focusing on the central role of hepatic stellate cells","volume":"25","author":"Akk\u0131z","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.actbio.2026.01.043_bib0087","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/ijms26010326","article-title":"Exploring molecular mechanisms of liver fibrosis","volume":"26","author":"Weiskirchen","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.actbio.2026.01.043_bib0088","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","article-title":"Hepatic stellate cells as key target in liver fibrosis","volume":"121","author":"Higashi","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2026.01.043_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122232","article-title":"Dually fibronectin\/CD44-mediated nanoparticles targeted disrupt the golgi apparatus and inhibit the hedgehog signaling in activated hepatic stellate cells to alleviate liver fibrosis","volume":"301","author":"Li","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2026.01.043_bib0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0091","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","article-title":"Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues","volume":"65","author":"Parola","year":"2019","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.actbio.2026.01.043_bib0092","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1039\/D3TB02790B","article-title":"Liver fibrosis: pathological features, clinical treatment and application of therapeutic nanoagents","volume":"12","author":"Chen","year":"2024","journal-title":"J. Mat. Chem. B"},{"key":"10.1016\/j.actbio.2026.01.043_bib0093","article-title":"Prognostic assessment of liver cirrhosis and its complications: current concepts and future perspectives","volume":"10","author":"G\u00fclcicegi","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.actbio.2026.01.043_bib0094","first-page":"433","article-title":"Efficacy and economic evaluation of nonbiological artificial liver therapy in acute-on-chronic hepatitis B liver failure","volume":"11","author":"Wu","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0095","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/14728214.2024.2341878","article-title":"Emerging synthetic drugs for the treatment of hepatic cirrhosis: a 2024 update","volume":"29","author":"Fallowfield","year":"2024","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.actbio.2026.01.043_bib0096","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12072-022-10430-8","article-title":"Clinical application of artificial liver and blood purification: expert consensus recommendations","volume":"17","author":"Chen","year":"2023","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.actbio.2026.01.043_bib0097","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2023.2219432","article-title":"M6P-modified solid lipid nanoparticles loaded with matrine for the treatment of fibrotic liver","volume":"30","author":"Tan","year":"2023","journal-title":"Drug Deliv."},{"key":"10.1016\/j.actbio.2026.01.043_bib0098","doi-asserted-by":"crossref","first-page":"7747","DOI":"10.1021\/acsami.2c19269","article-title":"Albumin-based silibinin nanocrystals targeting activated hepatic stellate cells for liver fibrosis therapy","volume":"15","author":"Luo","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.actbio.2026.01.043_bib0099","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1021\/acs.biomac.4c00691","article-title":"Cholinized-polymer functionalized lipid-based drug carriers facilitate liver fibrosis therapy via ultrafast liver-targeting delivery","volume":"25","author":"Yuan","year":"2024","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.actbio.2026.01.043_bib0100","doi-asserted-by":"crossref","first-page":"11239","DOI":"10.1021\/acsami.3c17670","article-title":"Dual-targeting macrophages and hepatic stellate cells by modified albumin nanoparticles for liver cirrhosis treatment","volume":"16","author":"Tan","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.actbio.2026.01.043_bib0101","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.actbio.2022.08.065","article-title":"Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy","volume":"152","author":"Zhou","year":"2022","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2026.01.043_bib0102","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jconrel.2024.02.022","article-title":"Engineered liposomes targeting hepatic stellate cells overcome pathological barriers and reverse liver fibrosis","volume":"368","author":"Wang","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2026.01.043_bib0103","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.actbio.2023.12.027","article-title":"Collagenase type I and probucol-loaded nanoparticles penetrate the extracellular matrix to target hepatic stellate cells for hepatic fibrosis therapy","volume":"175","author":"Wang","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2026.01.043_bib0104","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1016\/j.apsb.2023.08.020","article-title":"Remodeling of the liver fibrosis microenvironment based on nilotinib-loaded multicatalytic nanozymes with boosted antifibrogenic activity","volume":"13","author":"Jing","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.actbio.2026.01.043_bib0105","article-title":"The dual-target nanoparticles with ROS sensitivity inhibit the hedgehog signaling pathway and decrease oxidative stress in activated hepatic stellate cells to alleviate liver fibrosis","volume":"34","author":"Zhang","year":"2024","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.actbio.2026.01.043_bib0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122028","article-title":"Remodeling liver microenvironment by L-arginine loaded hollow polydopamine nanoparticles for liver cirrhosis treatment","volume":"295","author":"Wang","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2026.01.043_bib0107","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0016-5085(98)70487-1","article-title":"Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension","volume":"114","author":"Rockey","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.actbio.2026.01.043_bib0108","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jconrel.2023.01.052","article-title":"Liver fibrosis therapy based on biomimetic nanoparticles which deplete activated hepatic stellate cells","volume":"355","author":"Xia","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2026.01.043_bib0109","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3390\/pharmaceutics12060590","article-title":"Targeting activated hepatic stellate cells using collagen-binding Chitosan nanoparticles for siRNA delivery to fibrotic livers","volume":"12","author":"Azzam","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.actbio.2026.01.043_bib0110","doi-asserted-by":"crossref","first-page":"10492","DOI":"10.1021\/acsami.2c22579","article-title":"Liver-targeted delivery of small interfering RNA of C-C chemokine receptor 2 with tetrahedral framework nucleic acid attenuates Liver cirrhosis","volume":"15","author":"Tian","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.actbio.2026.01.043_bib0111","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121492","article-title":"Synergetic regulation of kupffer cells, extracellular matrix and hepatic stellate cells with versatile CXCR4-inhibiting nanocomplex for magnified therapy in liver fibrosis","volume":"284","author":"Wu","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2026.01.043_bib0112","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122134","article-title":"Retinol-binding protein-hijacking nanopolyplex delivering siRNA to cytoplasm of hepatic stellate cell for liver fibrosis alleviation","volume":"299","author":"Huang","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2026.01.043_bib0113","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jconrel.2023.08.021","article-title":"Reprogramming activated hepatic stellate cells by siRNA-loaded nanocarriers reverses liver fibrosis in mice","volume":"361","author":"Younis","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2026.01.043_bib0114","article-title":"Liver-targeted siRNA lipid nanoparticles treat hepatic cirrhosis by dual antifibrotic and anti-inflammatory activities","author":"Zhang","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2026.01.043_bib0115","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/mt.2010.4","article-title":"Rational design of immunostimulatory siRNAs","volume":"18","author":"Gantier","year":"2010","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.actbio.2026.01.043_bib0116","article-title":"RNA interference-induced innate immunity, off-target effect, or immune adjuvant?","volume":"8","author":"Z","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0117","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.2147\/IJN.S475234","article-title":"Stem cell-derived exosomes: natural intercellular messengers with versatile mechanisms for the treatment of diabetic retinopathy","volume":"19","author":"Song","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.actbio.2026.01.043_bib0118","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1038\/emm.2017.63","article-title":"Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases","volume":"49","author":"Lou","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.actbio.2026.01.043_bib0119","article-title":"MSC-derived exosomes attenuate hepatic fibrosis in primary sclerosing cholangitis through inhibition of Th17 differentiation","volume":"19","author":"Chen","year":"2024","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.actbio.2026.01.043_bib0120","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s12015-021-10313-9","article-title":"Comparative evaluation of anti-fibrotic effect of tissue specific mesenchymal stem cells derived extracellular vesicles for the amelioration of CCl4 induced chronic liver injury","volume":"18","author":"Gupta","year":"2022","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.actbio.2026.01.043_bib0121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41536-021-00132-4","article-title":"Small extracellular vesicles derived from interferon-\u03b3 pre-conditioned mesenchymal stromal cells effectively treat liver fibrosis","volume":"6","author":"Takeuchi","year":"2021","journal-title":"Npj Regen. Med."},{"key":"10.1016\/j.actbio.2026.01.043_bib0122","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s13287-022-03010-y","article-title":"Mesenchymal stem cell-derived exosomes protect against liver fibrosis via delivering miR-148a to target KLF6\/STAT3 pathway in macrophages","volume":"13","author":"Tian","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.actbio.2026.01.043_bib0123","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s12072-024-10717-y","article-title":"Mesenchymal stem cells-derived exosomes alleviate liver fibrosis by targeting Hedgehog\/SMO signaling","volume":"18","author":"Zong","year":"2024","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.actbio.2026.01.043_bib0124","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/10717544.2022.2030428","article-title":"Mesenchymal stem cell-originated exosomal circDIDO1 suppresses hepatic stellate cell activation by miR-141-3p\/PTEN\/AKT pathway in human liver fibrosis","volume":"29","author":"Ma","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.actbio.2026.01.043_bib0125","first-page":"692","article-title":"Advances in engineering circular RNA vaccines","volume":"13","author":"Zhang","year":"2024","journal-title":"Pathog. (Basel Switz.)"},{"key":"10.1016\/j.actbio.2026.01.043_bib0126","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114826","article-title":"Clinical delivery of circular RNA: lessons learned from RNA drug development","volume":"197","author":"Loan Young","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2026.01.043_bib0127","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","article-title":"AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.actbio.2026.01.043_bib0128","first-page":"11","article-title":"Cancer diagnosis: from tumor to liquid biopsy and beyond","volume":"19","author":"Vaidyanathan","year":"2018","journal-title":"Lab Chip"},{"key":"10.1016\/j.actbio.2026.01.043_bib0129","article-title":"Myeloperoxidase-sensitive T1 and T2 switchable MR imaging for diagnosis of nonalcoholic steatohepatitis","author":"Liu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2026.01.043_bib0130","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202305830","article-title":"Longitudinal Magnetic resonance imaging with ROS-responsive bilirubin nanoparticles enables monitoring of nonalcoholic steatohepatitis progression to cirrhosis","volume":"36","author":"Jung","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2026.01.043_bib0131","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.674786","article-title":"The potential application of magnetic nanoparticles for liver fibrosis theranostics","volume":"9","author":"Eftekhari","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.actbio.2026.01.043_bib0132","article-title":"Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T1-weighted MRI","volume":"120","author":"Zhang","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.actbio.2026.01.043_bib0133","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.1c10618","article-title":"Heterogeneous iron oxide\/dysprosium oxide nanoparticles target liver for precise magnetic resonance imaging of liver fibrosis","author":"Balachandran","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2026.01.043_bib0134","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00259-024-06894-5","article-title":"Non-invasive diagnosis of liver fibrosis via MRI using targeted gadolinium-based nanoparticles","volume":"52","author":"Wu","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"10.1016\/j.actbio.2026.01.043_bib0135","article-title":"Harnessing X-ray energy-dependent attenuation of bismuth-based nanoprobes for accurate diagnosis of liver fibrosis","volume":"8","author":"Wu","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.actbio.2026.01.043_bib0136","first-page":"2820","article-title":"Experimental characterization of spurious signals in magnetic nanoparticles enhanced microwave imaging of cancer","volume":"21","author":"Bucci","year":"2021","journal-title":"Sens. (Basel Switz.)"},{"key":"10.1016\/j.actbio.2026.01.043_bib0137","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2024.126143","article-title":"Silica-coated superparamagnetic iron oxide nanoparticles interacting with superoxide dismutase in the mouse primary hepatocytes","volume":"414","author":"Wang","year":"2024","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.actbio.2026.01.043_bib0138","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1021\/acsanm.1c04368","article-title":"Magnetic nanoparticle imaging: insight on the effects of magnetic interactions and hysteresis of tracers","volume":"5","author":"Barrera","year":"2022","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.actbio.2026.01.043_bib0139","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114083","article-title":"Clinical translation of nanomedicines: challenges, opportunities, and keys","volume":"181","author":"Younis","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2026.01.043_bib0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173832","article-title":"Advantages and challenges in nanomedicines for chronic liver diseases: a hepatologist\u2019s perspectives","volume":"893","author":"Ezhilarasan","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0141","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jconrel.2020.07.007","article-title":"Delivering the power of nanomedicine to patients today","volume":"326","author":"Germain","year":"2020","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"key":"10.1016\/j.actbio.2026.01.043_bib0142","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","article-title":"Extracellular vesicles as a next-generation drug delivery platform","volume":"16","author":"Herrmann","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.actbio.2026.01.043_bib0143","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s44355-025-00049-5","article-title":"Artificial intelligence-based agents in chronic liver disease: transforming diagnostic and therapeutic workflows through clinical decision-making","volume":"2","author":"Singh","year":"2025","journal-title":"Npj Gut Liver"},{"key":"10.1016\/j.actbio.2026.01.043_bib0144","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s12325-024-02781-5","article-title":"Artificial intelligence in liver diseases: recent advances","volume":"41","author":"Lu","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.actbio.2026.01.043_bib0145","article-title":"Nanotechnology and machine learning: a promising confluence for the advancement of precision medicine","volume":"12","author":"Musa","year":"2025","journal-title":"Intell.-Based Med."},{"key":"10.1016\/j.actbio.2026.01.043_bib0146","article-title":"Machine learning applications in nanomaterials: recent advances and future perspectives","volume":"500","author":"Yang","year":"2024","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.actbio.2026.01.043_bib0147","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41524-021-00520-w","article-title":"Two-step machine learning enables optimized nanoparticle synthesis","volume":"7","author":"Mekki-Berrada","year":"2021","journal-title":"Npj Comput. Mater."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706126000590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706126000590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:38:44Z","timestamp":1777621124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706126000590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":147,"alternative-id":["S1742706126000590"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2026.01.043","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanotechnology-driven biomaterials for chronic liver diseases: Stage-specific strategies for advanced theranostics","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2026.01.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Acta Materialia Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}